CRISPR Executive Reveals Surprising News

What I remember most clearly was the gasp…

The audience literally recoiled. People couldn’t believe what they had just heard.

Did he really just say that?!

It was November 2019. I was on the MIT campus, attending an invite-only biotechnology conference.

Industry executives and researchers gathered to share the latest breakthroughs. This was easily one of the highest-quality conferences I’d attended all year.

If the building had collapsed, the biotech industry would have ground to a halt. That’s the level of talent that was in attendance.

There were so many applications to attend the invite-only event that the executive editor had to turn away more people than there were in attendance.

What I learned that day shocked me.

And I believe it could signal one of the greatest wealth-building opportunities in history.

The God Key

During the conference, I attended a presentation on CRISPR-Cas9 genetic editing technology.

As readers likely already know, CRISPR technology can “edit” our DNA as if it were software code. It is a way to “program” the genome and remove the “typos” – or, in genetic terms, the “mutations” – from DNA.

In the past, I’ve referred to CRISPR as “the God Key” because of its potential to cure thousands of genetic diseases.

And we’re getting early indications that CRISPR technology works…

Back in February 2019, genetic editing companies began gene editing trials to treat a pair of blood disorders, beta thalassemia and sickle cell disease.

During the biotech conference, we heard about safety and efficacy data from the world’s first CRISPR genetic editing human trial. The results were outstanding.

Researchers had treated two patients with CRISPR therapy – one with sickle cell disease and the other with beta thalassemia. Both of those patients have now been free from disease symptoms since the treatment.

At the time, the beta thalassemia patient had not needed a blood transfusion in nine months. This was amazing considering patients with this disease typically need blood transfusions every two to four weeks.

And the sickle cell patient had not suffered a crisis in four months.

That bears repeating. The patients were free from symptoms and blood transfusion-independent for months. That has never happened before.

And in June 2020, close to the one-year anniversary of receiving the treatment, the sickle cell patient provided an update on her progress. The treatment has alleviated “virtually all the complications of her disorder.”

The CRISPR treatment has had similar long-term success with beta thalassemia. A second patient with the disease has been treated as well. Within five months, that patient was able to stop receiving blood transfusions.

Forgive me for stating the obvious, but this is just incredible.

This wasn’t a case of just an improvement or some demonstration of efficacy; the genetic therapy was a complete cure of their fatal conditions.

As incredible as that was, it was not what shocked me most…

The Audience Gasped

During the conference, I attended a roundtable discussion with an executive at a little-known CRISPR genetic editing company.

At first, the discussion was your usual fare. They were discussing the technology, efficacy, and clinical trials.

But then the executive did something very unusual. I’m not sure if he was flustered, was caught off guard, or simply let something slip. But he said three words. And the audience gasped.

Now, because this was a closed-door meeting, I’m not allowed to disclose precisely what was said.

But I’ll say this: After I heard that executive speak, I had total conviction that this technology worked as promised.

That’s why I’m holding my first-ever free biotechnology master class tonight at 8 p.m. ET. During the event, I’ll give details on my No. 1 small-cap biotech stock.

It’s a company I believe is on the verge of curing one of the world’s worst inherited diseases. And once that news breaks, I believe this stock could soar in a single day… perhaps going as high as 1,000%.

If you only ever invest in one biotech, it should be this one. I’ll see you tonight.

Regards,

Jeff Brown
Editor, The Bleeding Edge

Like what you’re reading? Send your thoughts to feedback@brownstoneresearch.com.